#USA #New York #Securities Fraud #Pomerantz LLP #Protalix BioTherapeutics

Recent Developments Surrounding Protalix BioTherapeutics

In light of recent events, Pomerantz LLP has initiated an investigation focused on the claims made by investors of Protalix BioTherapeutics, Inc. (NYSE: PLX). This inquiry was prompted by a noteworthy development that caught the attention of the financial community and investors alike. On October 17, 2025, Protalix, together with its partner Chiesi Global Rare Diseases, announced a negative opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency regarding their request to approve a new dosing regimen for their product, Elfabrio (pegunigalsidase alfa).

The CHMP's decision reflects a setback for the company, leading to a steep decline of 22.5% in Protalix's stock price, resulting in a per-share closing price of $1.86 on that day. The implications of this decline are significant, especially for investors who had placed their trust and capital in the company's future prospects.

Pomerantz’s Role in Protecting Investors

Pomerantz LLP, a prominent law firm with a strong history of fighting for the rights of investors, is now reaching out to individuals affected by these developments. Danielle Peyton from the firm has urged concerned investors to contact her through email or phone for more information and to discuss potential actions. As a firm recognized for its expertise in corporate and securities class litigation, Pomerantz has a long-standing tradition of advocating for victims of securities fraud, breaches of fiduciary duty, and overall corporate misconduct.

Founded by the esteemed Abraham L. Pomerantz, the firm has spent over 85 years championing the rights of those impacted by unlawful business practices. Notably, the firm has succeeded in recovering significant financial awards for class members in various cases, reflecting its commitment to seeking justice for investors.

Investigating Securities Fraud and Unlawful Practices

The core of Pomerantz’s investigation is whether Protalix and its top executives engaged in any fraudulent behavior or violated securities laws. The timing of the stock plunge poses serious questions about the company's disclosure practices and the accuracy of the information provided to investors prior to this announcement. As news of this investigation spreads, more investors are expected to come forward, potentially leading to a larger class action claim.

Call to Action for Affected Investors

For investors who feel they have been misled or faced financial losses as a result of the company's practices, the timing to act is crucial. Pomerantz invites those affected by the recent stock decline and subsequent fallout to connect directly with their team for a comprehensive assessment of their situations. The law firm is keen on guiding investors through the legal complexities associated with securities fraud and assisting them in maximizing their claims.

As the situation develops, more details regarding the investigation will emerge. To stay informed, interested participants can keep in touch through the firm's website or contact Danielle Peyton for updates regarding the class action proceedings.

Conclusion

The investigation by Pomerantz LLP signifies a critical moment for investors in Protalix BioTherapeutics, as those affected by the sudden stock decrease are given an opportunity to seek restitution. With a legacy of securing justice for those harmed by corporate misconduct, Pomerantz is poised to assist affected parties through this challenging time. Investors are encouraged to act promptly and ensure their rights are protected as legal proceedings unfold.